| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-24 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | 9.090 | 7.700 | -1.3900 | ||||
| REV | 6.230B | 4.969B | -1.261B |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Moderna (NASDAQ: MRNA) through any online brokerage.
Other companies in Moderna’s space includes: Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Mirati Therapeutics (NASDAQ:MRTX), Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR).
The latest price target for Moderna (NASDAQ: MRNA) was reported by UBS on January 21, 2022. The analyst firm set a price target for 221.00 expecting MRNA to rise to within 12 months (a possible 38.06% upside). 32 analyst firms have reported ratings in the last year.
The stock price for Moderna (NASDAQ: MRNA) is $160.07 last updated Fri Jan 21 2022 21:00:04 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Moderna.
Moderna’s $Q4 earnings are confirmed for after-market on February 24, 2022.
There is no upcoming split for Moderna.
Moderna is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.